AGENUS INC (AGEN)
US00847G8042 - Common Stock
AGEN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. AGEN may be in some trouble as it scores bad on both profitability and health. AGEN is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year AGEN has reported negative net income.
AGEN had a negative operating cash flow in the past year.
In the past 5 years AGEN always reported negative net income.
AGEN had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
AGEN has a Return On Assets of -95.55%. This is in the lower half of the industry: AGEN underperforms 74.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -95.55% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-45.6%
ROA(5y)-58.14%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 99.61%, AGEN belongs to the top of the industry, outperforming 98.76% of the companies in the same industry.
AGEN's Gross Margin has been stable in the last couple of years.
AGEN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 99.61% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.23%
GM growth 5YN/A
2. Health
2.1 Basic Checks
AGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AGEN has more shares outstanding
The number of shares outstanding for AGEN has been increased compared to 5 years ago.
AGEN has a worse debt/assets ratio than last year.
2.2 Solvency
AGEN has an Altman-Z score of -14.29. This is a bad value and indicates that AGEN is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of AGEN (-14.29) is worse than 81.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -14.29 |
ROIC/WACCN/A
WACC11.49%
2.3 Liquidity
A Current Ratio of 0.19 indicates that AGEN may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.19, AGEN is doing worse than 97.70% of the companies in the same industry.
AGEN has a Quick Ratio of 0.19. This is a bad value and indicates that AGEN is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.19, AGEN is doing worse than 97.35% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.19 | ||
| Quick Ratio | 0.19 |
3. Growth
3.1 Past
AGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.46%, which is quite impressive.
AGEN shows a strong growth in Revenue. In the last year, the Revenue has grown by 59.00%.
The Revenue has been growing by 33.56% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)31.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.75%
Revenue 1Y (TTM)59%
Revenue growth 3Y21.03%
Revenue growth 5Y33.56%
Sales Q2Q%3.28%
3.2 Future
AGEN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.14% yearly.
The Revenue is expected to grow by 11.23% on average over the next years. This is quite good.
EPS Next Y11.31%
EPS Next 2Y16.62%
EPS Next 3Y10.61%
EPS Next 5Y10.14%
Revenue Next Year-9.08%
Revenue Next 2Y11.25%
Revenue Next 3Y3.03%
Revenue Next 5Y11.23%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
AGEN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AGEN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.62%
EPS Next 3Y10.61%
5. Dividend
5.1 Amount
AGEN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AGENUS INC
NASDAQ:AGEN (1/13/2025, 12:32:55 PM)
3.105
-0.02 (-0.48%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners41.6%
Inst Owner Change0%
Ins Owners1.29%
Ins Owner Change0.24%
Market Cap72.84M
Analysts74.55
Price Target8.16 (162.8%)
Short Float %12.66%
Short Ratio5.47
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-50.38%
Min EPS beat(2)-71.27%
Max EPS beat(2)-29.49%
EPS beat(4)1
Avg EPS beat(4)-59.05%
Min EPS beat(4)-142.76%
Max EPS beat(4)7.33%
EPS beat(8)3
Avg EPS beat(8)-28.4%
EPS beat(12)6
Avg EPS beat(12)-18.63%
EPS beat(16)9
Avg EPS beat(16)-12.49%
Revenue beat(2)0
Avg Revenue beat(2)-44.48%
Min Revenue beat(2)-62.51%
Max Revenue beat(2)-26.46%
Revenue beat(4)1
Avg Revenue beat(4)-11.73%
Min Revenue beat(4)-62.51%
Max Revenue beat(4)74.6%
Revenue beat(8)3
Avg Revenue beat(8)0.96%
Revenue beat(12)6
Avg Revenue beat(12)7.79%
Revenue beat(16)8
Avg Revenue beat(16)9.27%
PT rev (1m)0%
PT rev (3m)-17.95%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1837.45%
EPS NY rev (1m)0%
EPS NY rev (3m)-19.92%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.48%
Revenue NY rev (1m)-13.03%
Revenue NY rev (3m)-14.42%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.45 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-11.24
EYN/A
EPS(NY)-9.09
Fwd EYN/A
FCF(TTM)-7.28
FCFYN/A
OCF(TTM)-7.25
OCFYN/A
SpS6.84
BVpS-12.46
TBVpS-13.68
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -95.55% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 99.61% | ||
| FCFM | N/A |
ROA(3y)-45.6%
ROA(5y)-58.14%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.23%
GM growth 5YN/A
F-Score4
Asset Turnover0.67
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 4.75% | ||
| Cap/Sales | 0.45% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.19 | ||
| Quick Ratio | 0.19 | ||
| Altman-Z | -14.29 |
F-Score4
WACC11.49%
ROIC/WACCN/A
Cap/Depr(3y)445.11%
Cap/Depr(5y)290.7%
Cap/Sales(3y)23.98%
Cap/Sales(5y)15.79%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.75%
EPS Next Y11.31%
EPS Next 2Y16.62%
EPS Next 3Y10.61%
EPS Next 5Y10.14%
Revenue 1Y (TTM)59%
Revenue growth 3Y21.03%
Revenue growth 5Y33.56%
Sales Q2Q%3.28%
Revenue Next Year-9.08%
Revenue Next 2Y11.25%
Revenue Next 3Y3.03%
Revenue Next 5Y11.23%
EBIT growth 1Y52.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year12.05%
EBIT Next 3Y-4.29%
EBIT Next 5Y-7.26%
FCF growth 1Y14.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-12.65%
OCF growth 3YN/A
OCF growth 5YN/A